Doubling down on breast cancer

See allHide authors and affiliations

Science  01 Feb 2019:
Vol. 363, Issue 6426, pp. 495-496
DOI: 10.1126/science.363.6426.495-c

Triple-negative breast cancer (TNBC) is a highly aggressive form of cancer that preferentially affects women of African ancestry. An incomplete understanding of the cellular signaling mechanisms that drive TNBC growth has slowed the development of effective therapies. A study of an extracellular matrix protein named Tinagl1 may offer new hope. Shen et al. found that therapeutic delivery of Tinagl1 suppresses tumor growth and metastasis in mouse models of TNBC. Tinagl1 exerts its anti-cancer effect by simultaneously inhibiting two distinct signaling pathways: the epidermal growth factor receptor and the focal adhesion kinase pathways. TNBC patients whose tumors showed high expression levels of Tinagl1 had better clinical outcomes.

Cancer Cell 35, 1 (2019).

Navigate This Article